NCT05756972View on ClinicalTrials.gov

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

64

Participants

Timeline

Start Date

June 26, 2023

Primary Completion Date

September 13, 2024

Study Completion Date

December 31, 2025

Conditions

NSCLC

Interventions

DRUG

PM8002

IV infusion

DRUG

Carboplatin

IV infusion

DRUG

Pemetrexed

IV infusion

Trial Locations (1)

519041

Medical Ethics Committee of Guangdong Provincial People's Hospital, Guangzhou

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Biotheus Inc.

INDUSTRY